JMP Securities Reaffirms "Market Outperform" Rating for Savara (NASDAQ:SVRA)

JMP Securities reiterated their market outperform rating on shares of Savara (NASDAQ:SVRA - Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. JMP Securities currently has a $9.00 price objective on the stock.

Several other analysts also recently weighed in on SVRA. HC Wainwright lowered their target price on Savara from $10.00 to $6.00 and set a "buy" rating for the company in a research note on Wednesday, November 13th. Evercore ISI reissued an "in-line" rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $10.17.

Savara Stock Up 7.0 %

Shares of SVRA traded up $0.21 during mid-day trading on Thursday, reaching $3.23. 1,310,923 shares of the stock traded hands, compared to its average volume of 1,271,579. The firm has a market cap of $554.33 million, a price-to-earnings ratio of -7.51 and a beta of 0.92. The stock has a fifty day simple moving average of $3.48 and a 200 day simple moving average of $3.99. Savara has a 12-month low of $2.82 and a 12-month high of $5.70. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). Sell-side analysts expect that Savara will post -0.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Savara news, Director Joseph S. Mccracken purchased 20,000 shares of the firm's stock in a transaction dated Tuesday, November 19th. The stock was acquired at an average cost of $2.95 per share, with a total value of $59,000.00. Following the acquisition, the director now owns 210,837 shares of the company's stock, valued at approximately $621,969.15. This represents a 10.48 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Matthew Pauls sold 54,702 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the sale, the chief executive officer now owns 1,536,379 shares in the company, valued at approximately $5,085,414.49. This trade represents a 3.44 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.13% of the company's stock.

Hedge Funds Weigh In On Savara

A number of hedge funds and other institutional investors have recently bought and sold shares of SVRA. Bank of New York Mellon Corp increased its position in Savara by 12.5% in the second quarter. Bank of New York Mellon Corp now owns 288,325 shares of the company's stock worth $1,162,000 after buying an additional 32,142 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Savara by 967.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 44,008 shares of the company's stock worth $177,000 after acquiring an additional 39,886 shares during the period. Principal Financial Group Inc. lifted its position in Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company's stock valued at $72,000 after purchasing an additional 6,973 shares during the last quarter. Victory Capital Management Inc. acquired a new position in Savara during the 2nd quarter valued at about $527,000. Finally, Choreo LLC bought a new position in Savara in the 2nd quarter worth about $59,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.